Patents Assigned to Merck
  • Liquid-crystalline medium
    Patent number: 9822302
    Abstract: The compounds of the formula I, and a liquid-crystalline medium, preferably having a nematic phase and negative dielectric anisotropy, which comprises a) one or more compounds of the formula I and b) one or more compounds of the formulae II-1 to II-4, in which the parameters have the meanings defined herein, are suitable for use in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALC, FFS or IPS effect.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: November 21, 2017
    Assignee: Merck Patent GmbH
    Inventors: Martin Engel, Thorsten Kodek, Ingo Almeroth, Rocco Fortte
  • Method for preparing crystalline insulin
    Patent number: 9822158
    Abstract: A method for crystallizing insulin or insulin analogs under alkaline conditions and purifying the insulin or insulin analog crystals by filtering through a filter and drying the insulin or insulin analog crystals captured on the filter to produce crystalline insulin or insulin analog crystal compositions is described. In particular aspects, the method may be used to crystalize insulin glargine.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: November 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, William Perry, Mark C. Sleevi, Luis Sierra
  • Pharmaceutical formulation comprising losartan potassium and chlorthalidone
    Patent number: 9820973
    Abstract: The invention is a pharmaceutical tablet formulation comprising between about 12.5 mg and 100 mg losartan potassium, between about 6.25 mg and about 50 mg chlorthalidone, and sodium bicarbonate in an amount between about 1.0% and about 10.0% by weight.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: November 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jan-Piet Wijgergangs, Jocominus Antonius Maria Zwinkels, Albert Falivene Aldea
  • Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
    Patent number: 9822107
    Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein ring R1, R2, R3, R4, ring B, and the subscript r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: November 21, 2017
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Brian M. Andresen, Kenneth L. Arrington, Ryan D. Otte, John Michael Ellis, John W. Butcher, Alan B. Northrup, Joel S. Robichaud, Jacques Yves Gauthier, Jean-Francois Fournier
  • Black polymer particles
    Patent number: 9822232
    Abstract: This invention relates to a process for the preparation of a dispersion comprising black polymer particles, such black polymer particles prepared by the process, the use of the dispersion and the black polymer particles in electrophoretic fluids, and electrophoretic display devices comprising such fluids.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 21, 2017
    Assignees: Merck Patent GmbH, The Queen's University of Belfast
    Inventors: Louise D. Farrand, Sarah Norman
  • SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES
    Publication number: 20170327817
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Application
    Filed: January 27, 2016
    Publication date: November 16, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA
    Publication number: 20170327741
    Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Application
    Filed: December 8, 2015
    Publication date: November 16, 2017
    Applicant: Merck Patent GmbH
    Inventors: Detlef PAULUTH, Kevin ADLEM, Owain Llyr PARRI, Rachel TUFFIN, Hassan ARASI, Patricia Eileen SAXTON
  • PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170327490
    Abstract: The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 27, 2015
    Publication date: November 16, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: NIGEL LIVERTON, SCOTT D. KUDUK, DOUGLAS BESHORE, YUNFU LUO, NA MENG, TINGTING XU
  • Carbazole derivatives for organic electroluminescence devices
    Patent number: 9818948
    Abstract: The present invention describes carbazole derivatives formula (1), where the following applies to the symbols used: Y is on each occurrence, identically or differently, CR or N; X is selected from C(R1)2, O, S, PR1, P(?O)R1 or BR1; characterized in that at least one group R is present which stands, identically or differently on each occurrence, for a group of the following formula (2), and/or in that at least one group R1 is present which stands for a group of the following formula (3) or (4), in particular for use as triplet matrix materials in organic electroluminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: November 14, 2017
    Assignee: Merck Patent GmbH
    Inventors: Anja Jatsch, Amir Hossain Parham, Christof Pflumm, Philipp Stoessel, Jonas Valentin Kroesser, Rémi Manouk Anémian, Thomas Eberle
  • Polymers containing substituted triarylamine units and electroluminescent devices containing said polymers
    Patent number: 9815940
    Abstract: The present invention relates to polymers which contain triarylamine repeating units that are substituted in the ortho position, methods for the production thereof, and the use thereof in electronic devices, especially in organic electroluminescent devices, so-called OLEDs (OLED=Organic Light Emitting Diode). The present invention also relates to organic electroluminescent devices which contain said polymers.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: November 14, 2017
    Assignee: Merck Patent GmbH
    Inventors: Fabrice Eckes, Katja Stegmaier, Anna Hayer, Holger Heil, Dominik Joosten
  • TrkA kinase inhibitors, compositions and methods thereof
    Patent number: 9815846
    Abstract: The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 14, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi-Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Kerim Babaoglu, Dongfang Meng, Jane Wu, Ping Liu, Harold B. Wood, Jianming Bao, Chun Sing Li, Qinghua Mao, Zhiqi Qi
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9815861
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 14, 2017
    Assignees: Alectos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Pyrimidone carboxamide compounds as PDE2 inhibitors
    Patent number: 9815796
    Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: November 14, 2017
    Assignees: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhiqiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
  • Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
    Patent number: 9815836
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: November 14, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Henry Yu, Ruoxi Lan, Catherine Jorand-Lebrun, Theresa L. Johnson, Andreas Goutopoulos
  • Optical device with power supply system
    Patent number: 9817256
    Abstract: The invention pertains to an optical device comprising at least one glass or polymer area, whereby an active matrix is located in contact with the at least one glass or polymer area, the optical device comprises a power supply system located between a first auxiliary plane and a second auxiliary-plane parallel to a glass or polymer area, and a distance L from a third auxiliary-plane or a fourth auxiliary-plane approximately perpendicular to the glass or polymer area. The invention pertains also to a power supply system for such an optical device.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 14, 2017
    Assignee: Merck Patent GmbH
    Inventors: Casper Van Oosten, Felix Schlosser
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20170320882
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).
    Type: Application
    Filed: July 21, 2017
    Publication date: November 9, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Xianhai Huang, Ronald D. Ferguson, Wei Zhou, Christopher W. Boyce, Phieng Siliphaivanh, David J. Witter, Milana M. Maletic, Joseph A. Kozlowski, Kevin J. Wilson
  • NON-METALLIC PIGMENTS HAVING METAL PROPERTIES
    Publication number: 20170321057
    Abstract: The present invention relates to non-metallic interference pigments, in particular laminar interference pigments, which comprise a thin high-refractive layer and an outermost layer that contains crystalline carbon in the form of graphite and/or graphene. The invention also relates to a method for producing such pigments and the use of the thus produced pigments.
    Type: Application
    Filed: November 23, 2015
    Publication date: November 9, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Reinhold RUEGER, Bjoern KLEIST
  • BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170320876
    Abstract: The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: November 20, 2015
    Publication date: November 9, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: SCOTT D. KUDUK, THOMAS S. REGER, ANTHONY J. ROECKER
  • Method For The Production of Praziquantel and Precursors Thereof
    Publication number: 20170320873
    Abstract: The present invention relates to methods for the production of enantiopure or enantioenriched Praziquantel precursors and to methods for the production of enantiopure or enantioenriched Praziquantel comprising the methods for the production of the Praziquantel precursors. The present invention further relates to compounds or intermediates useful in such methods.
    Type: Application
    Filed: November 19, 2015
    Publication date: November 9, 2017
    Applicant: Merck Patent GmbH
    Inventors: David MAILLARD, Andreas WAECHTLER, Jeremy MAURIN, Ewgenij WAKARESKO, Christian JASPER
  • PROCESS FOR IMPROVING THE SOLUBILITY OF CELL CULTURE MEDIA
    Publication number: 20170321186
    Abstract: The invention relates to a process for improving the solubility of dry cell culture media. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using a stepwise procedure in which the amino acids present in the non-dissolving part are identified and added to a new batch in other particle sizes significantly reduces that problem.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 9, 2017
    Applicant: Merck Patent GmbH
    Inventor: Joerg VON HAGEN